16 maj: Kreditbanken A/S: kvartalrapport 1. kvartal 2019
16 maj: Aktietilbagekøbsprogram i SP Group A/S
16-05-2019 15:42:38

Genmab Announces Data to be Presented at 24th EHA Annual Congress

Media Release

Copenhagen, Denmark, May 16, 2019

15 industry-sponsored abstracts featuring Genmab programs selected for presentation at EHA Annual Congress

Genmab A/S (Nasdaq Copenhagen: GEN) announced today that 15 industry sponsored abstracts regarding Genmab programs were accepted for presentation at the 24th European Hematology Association (EHA) Annual Congress 2019 in Amsterdam, the Netherlands, taking place June 13-16, 2019. A list of accepted Industry-sponsored abstracts featured at the congress includes 14 daratumumab abstracts, four of which were accepted for oral presentations, including a presentation of the Phase III CASSIOPEIA data, which the Scientific Program Committee of the EHA selected for presentation during the Presidential Symposium, which showcases abstracts that represent innovative research in hematology. In addition, one abstract features Genmab’s proprietary DuoBody®-CD3xCD20 product. The abstracts have been published on the EHA website and may be accessed via www.ehaweb.org

 “The presentation of impressive pre-clinical data on our DuoBody-CD3xCD20 program exemplifies how Genmab is advancing its proprietary product pipeline using our strong expertise in antibody drug development to create truly differentiated products to help patients with hematologic malignancies. We are also very pleased that the EHA has selected the CASSIOPEIA data for presentation during the prestigious Presidential Symposium as it reinforces Genmab’s impactful contribution to multiple myeloma treatment,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

Industry-Sponsored Abstracts are as follows:

DuoBody-CD3xCD20:

Potent Anti-tumor Activity of DuoBody-CD3xCD20 in Pre-clinical Models In Vitro and In Vivo – Poster presentation, Saturday, June 15, 5:30 PM – 7:00 PM CEST

Daratumumab (Submitted by Janssen Biotech, Inc.):

Phase 3 Randomized Study of Daratumumab, Bortezomib, Thalidomide, and Dexamethasone (VTd) Versus VTd in Transplant-eligible Newly Diagnosed Multiple Myeloma: Part 1 CASSIOPEIA Results – Oral presentation, Friday, June 14, 3:45 PM – 4:00 PM CEST

Efficacy of Daratumumab, Bortezomib, Thalidomide, and Dexamethasone in Transplant-eligible Newly Diagnosed Multiple Myeloma Based Minimal Residual Disease Status: Analysis of CASSIOPEIA – Oral presentation, Saturday, June 15, 4:45 PM – 5:00 PM CEST

Randomized, Open-label, Non-inferiority, Phase 3 Study of Subcutaneous Versus Intravenous Daratumumab Administration in Patients with Relapsed or Refractory Multiple Myeloma: COLUMBA – Oral presentation, Saturday, June 15, 11:30 AM – 11:45 AM CEST

Subcutaneous Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Amyloid Light Chain Amyloidosis: Updated Safety Run-in Results of ANDROMEDA – Oral presentation, Saturday, June 15, 5:00 PM – 5:15 PM CEST

Stem Cell Yield and Transplantation in Transplant-eligible Newly Diagnosed Multiple Myeloma Patients Receiving Daratumumab, Bortezomib, Thalidomide, and Dexamethasone: Phase 3 CASSIOPEIA Study – Poster presentation, Friday, June 14, 5:30 PM – 7:00 PM CEST

Impact of Age on Efficacy and Safety of Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Transplant-ineligible Newly Diagnosed Multiple Myeloma: MAIA – Poster presentation, Friday, June 14, 5:30 PM – 7:00 PM CEST

Faster and Sustained Improvement in Health-related Quality of Life in Transplant-ineligible Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) Versus Rd: MAIA – Poster presentation, Friday, June 14, 5:30 PM – 7:00 PM CEST

Efficacy and Safety of Daratumumab, Lenalidomide, and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Subgroup Analysis of POLLUX Based on Cytogenetic Risk – Poster presentation, Friday, June 14, 5:30 PM – 7:00 PM CEST

Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Subgroup Analysis of CASTOR Based on Cytogenetic Risk – Poster presentation, Friday, June 14, 5:30 PM – 7:00 PM CEST

Characterization of Treatments and Real-life Outcomes in Patients with Newly Diagnosed Multiple Myeloma Who Received Frontline Autologous Stem Cell Transplantation in Sweden – Poster presentation, Friday, June 14, 5:30 PM – 7:00 PM CEST

Characterization of Frontline Treatment Patterns and the Proportion of Patients Reaching Subsequent Lines of Therapy in Transplant-eligible Patients with Newly Diagnosed Multiple Myeloma – Poster presentation, Friday, June 14, 5:30 PM – 7:00 PM CEST

Improvement in Health-related Quality of Life for Newly Diagnosed Multiple Myeloma Transplant-eligible Patients Treated with Daratumumab, Bortezomib, Thalidomide, and Dexamethasone: CASSIOPEIA  – Poster presentation, Saturday, June 15, 5:30 PM – 7:00 PM CEST

Results of the Daratumumab Monotherapy Early Access Treatment Protocol in Patients from Europe and Russia with Relapsed or Refractory Multiple Myeloma – Poster presentation, Saturday, June 15, 5:30 PM – 7:00 PM CEST

Comparative Effectiveness of Frontline Treatments for Patients with Newly Diagnosed Multiple Myeloma Who are Transplant-ineligible – Poster presentation, Saturday, June 15, 5:30 PM – 7:00 PM CEST

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.  Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications.  Daratumumab is in clinical development for additional multiple myeloma indications and other blood cancers.  A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis.  Genmab also has a broad clinical and pre-clinical product pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, the HexaBody® platform, which creates effector function enhanced antibodies and the HexElect® platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products.  Genmab has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com.

Contact:          

Marisol Peron, Corporate Vice President, Communications & Investor Relations

T: +1 609 524 0065; E: mmp@genmab.com

For Investor Relations:

Andrew Carlsen, Senior Director, Investor Relations

T: +45 3377 9558; E: acn@genmab.com

This Media Release contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody®; HexElect®; and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Pharmaceutica NV.

Media Release no. 07

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

Genmab A/S

Kalvebod Brygge 43

1560 Copenhagen V

Denmark

Attachment

logo.jpg

Relateret indhold
16 sep - 
Mandagens aktier: Svingende Lundbeck endte lavere i rød..
16 sep - 
Aktier/middag: Lundbeck vender rundt og topper rødt C25..
16 sep - 
Aktier/åbning: Lundbeck helt i bund på milliardopkøb i ..
Relateret debat
16 sep - 
Dejligt
16 sep - 
GENMAB/GUGGENHEIM: LØFTER KURSMÅLET MED 12..
13 sep - 
13.9.19: “Novartis' ofatumumab to be 'strong' competito..
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
16 sep
GEN
GENMAB/GUGGENHEIM: LØFTER KURSMÅLET MED 12,4 PCT. 06:36 Finanshuset Guggenheim Securities løfter sit..
9
13 sep
GEN
13.9.19: “Novartis' ofatumumab to be 'strong' competitor to Roche drug, says Deutsche Bank Deutsche ..
5
12 sep
GEN
https://classic.nordnet.dk/mux/web/analys/nyheter/visaNyhet.html?itemid=538639013&sourcecode=ddk
5
13 sep
GEN
BofA/Merrill analyst Sachin Jain upgraded Genmab to Buy from Neutral with an increased price target ..
2
13 sep
GEN
Vi kunne jo starte med 1000 hver, men det flytter nok ikke det store. Tror på Genmab er et guldæg, e..
1
13 sep
GEN
Mit svar var et forsøg på at besvare QueenMary og IKKE nogen anbefaling. Har desværre heller ikke se..
1
13 sep
GEN
GENMAB: POSITIVE RESULTATER I KOMBINATIONSSTUDIE MED DARZALEX - NY 16:22Biotekselskabet Genmab kan g..
1
13 sep
GEN
Kan du så ikke bare købe 20.000 stk. så sker der nok lidt med kursen.   Taastrup 
1
13 sep
GEN
Når man skimmer de resultater, der deles på Twitter, lader det til at der er tale om et meget succes..
1
13 sep
GEN
Company Announcement Details from the ASCLEPIOS I & II studies of subcutaneous ofatumumab (OMB157) ..
1

Riksbanken nedtoner behov for renteforhøjelser - svensk krone svækkes

17-09-2019 09:48:14
Den svenske centralbank, Riksbanken, ser ikke længere samme behov for at stramme pengepolitikken. Det fremgår af referatet af det seneste rentemøde den 4. september.Her var rentekomitéens medlemmer enige om, at de økonomiske udsigter er forværret, og at riskoen for en hurtigere afmatning er øget. Årsagen er blandt andet handelskonflikten mellem USA og Kina og usikkerheden om Storbritanniens udtræd..

Aktier/åbning: Lundbeck helt i bund på milliardopkøb i rødt marked

16-09-2019 09:13:54
Lundbecks melding om at ville købe amerikanske Alder Biopharmaceuticals i en handel, der er værdisat op til 1,95 mia. dollar - eller omkring 13 mia. kr., får i de første handler investorerne til at sende aktien ned.Aktien falder helt til bunds i eliteindekset med et fald på 3,6 pct. til 228 kr. mandag morgen, i et marked der samlet i C25 falder 0,5 pct. til indeks 1140,69.Lundbeck er i negativt ra..

Prisen på råolie ryger i vejret efter angreb i Saudi-Arabien

Relaterede nyheder
16-09-2019 06:34:09
Prisen på råolie stiger med over ti procent efter lørdagens droneangreb mod to olieanlæg i Saudi-Arabien.Dermed er der også udsigt til dyrere benzin.Da handlen med råolie begyndte klokken 00.00 dansk tid hoppede prisen op med omkring 15 procent, skriver nyhedsbureauet Reuters. Efter omkring en time ligger prisen på en tønde Nordsø-olie omkring 13 procent højere i lidt over 68 dollar.Det var på for..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Sydbank i fokus efter uro i bestyrelsen
2
Topchef efter salg for 50 mio. kr.: "Måske dummeste beslutning ever"
3
Ørsted sælger Radius i millardhandel til SEAS-NVE - NY
4
Sydbank/Nordnet: Det lægger op til mærkbare besparelser - NY
5
Aktier/åbning: DSV og Mærsk trækker ned i C25 efter Fedex-nedjustering

Relaterede aktiekurser

Genmab A/S 1.390,00 1,9% Stigning i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
18. september 2019 17:35:41
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190829.2 - EUROWEB3 - 2019-09-18 17:35:41 - 2019-09-18 17:35:41 - 1 - Website: OKAY